Metformin for cancer prevention : a reason for optimism
Mené au Japon sur 151 patients non diabétiques ayant présenté un ou plusieurs adénomes colorectaux traités par résection endoscopique entre 2011 et 2014 (durée de suivi : 1 an), cet essai multicentrique de phase III évalue la toxicité d'une faible dose quotidienne de metformine ainsi que son efficacité pour réduire le risque de récidive
Obesity and its metabolic complications, including diabetes, have been associated with an increased risk of several cancers.1 The global obesity epidemic has fuelled a sustained rise in obesity-related cancers, especially in resource-poor regions with few options for population-based screening. Thus, the potential use of metformin as a novel cancer prevention strategy has generated much excitement in view of its low cost, favourable safety profile, and its potential for biological specificity in disrupting the association between obesity and cancer.
The Lancet Oncology , commentaire, 2015